GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achillion Pharmaceuticals Inc (NAS:ACHN) » Definitions » Book Value per Share

Achillion Pharmaceuticals (Achillion Pharmaceuticals) Book Value per Share : $1.55 (As of Sep. 2019)


View and export this data going back to 2006. Start your Free Trial

What is Achillion Pharmaceuticals Book Value per Share?

Achillion Pharmaceuticals's book value per share for the quarter that ended in Sep. 2019 was $1.55.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

Achillion Pharmaceuticals's current price is $6.76. Its book value per share for the quarter that ended in Sep. 2019 was $1.55. Hence, today's PB Ratio of Achillion Pharmaceuticals is 4.35.


Achillion Pharmaceuticals Book Value per Share Historical Data

The historical data trend for Achillion Pharmaceuticals's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achillion Pharmaceuticals Book Value per Share Chart

Achillion Pharmaceuticals Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.39 3.29 2.92 2.35 1.92

Achillion Pharmaceuticals Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.02 1.92 1.80 1.67 1.55

Competitive Comparison of Achillion Pharmaceuticals's Book Value per Share

For the Biotechnology subindustry, Achillion Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Achillion Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Achillion Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Achillion Pharmaceuticals's PB Ratio falls into.



Achillion Pharmaceuticals Book Value per Share Calculation

Achillion Pharmaceuticals's Book Value Per Share for the fiscal year that ended in Dec. 2018 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(266.01-0.00)/138.72
=1.92

Achillion Pharmaceuticals's Book Value Per Share for the quarter that ended in Sep. 2019 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(217.22-0.00)/139.89
=1.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Achillion Pharmaceuticals  (NAS:ACHN) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Achillion Pharmaceuticals Book Value per Share Related Terms

Thank you for viewing the detailed overview of Achillion Pharmaceuticals's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Achillion Pharmaceuticals (Achillion Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
300 George Street, New Haven, CT, USA, 06511
Achillion Pharmaceuticals Inc is a biotechnology company that seeks to discover and commercialize treatments for rare diseases. The company is engaged solely in the discovery and development of innovative small-molecule drug therapies for infectious diseases and immune system disorders. Achillion specializes in structural biology, medicinal chemistry, and antimicrobial discovery research. The company generates revenue from product sales, regulatory and commercialization milestones, and royalties. Achillion also uses collaborative and licensing agreements.
Executives
Joseph Truitt director, officer: Chief Executive Officer C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Kurt Graves director C/O ACHILLION PHARMACEUTICALS INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Michael D Kishbauch director 18 CHERRYVILLE RD, FLEMINGTON NJ 08822
Jason S Fisherman director C/O ADVENT INTERNATIONAL CORP, 75 STATE ST 29TH FLOOR, BOSTON MA 02104
Van Nostrand Robert L director C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Nicole Vitullo director 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Martha E Manning officer: General Counsel 700 PENNSYLVANIA DR, EXTON PA 19341
Frank Verwiel director C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005
Paul E Firuta officer: EVP, Chief Commercial Officer 550 HILLS DRIVE, THIRD FLOOR, BEDMINSTER NJ 07921
Steven Zelenkofske officer: EVP, Chief Medical Officer 120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920
Mary Kay Fenton officer: Chief Financial Officer ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511
Milind Deshpande director, officer: Chief Executive Officer ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511
Johnson & Johnson Innovation - Jjdc, Inc. 10 percent owner 410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Johnson & Johnson 10 percent owner ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ 08933
David Apelian officer: Chief Medical Officer C/O ACHILLION PHARMACEUTICALS, INC, 300 GEORGE STREET, NEW HAVEN CT 06511